Fidelity SPDR Advertisement
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 480
Posts 80,845
Boards Moderated 22
Alias Born 09/05/02
160x600 placeholder
S&P 500, Dow Close At Record Highs
The S&P 500 and Dow Jones Industrial Average closed at record levels on Thursday as investors welcomed the Federal Reserve's commitment to low interest rates long after the ending of monetary stimulus.
Top Equities Stories Of The Day
Newest iPhones Hit the Market Down Under
This Man's Job: Make Bill Gates Richer
Diageo Launches, Prices Euro Denominated Bonds
U.S. Hot Stocks: Hot Stocks to Watch
Senate Confirms Sheets as Treasury Under Secretary for International Affairs
Americans Support Striking Islamic Militants, Poll Shows
U.S. Hog Futures Fall Sharply on Supply Concerns, Cattle Decline
Li Na Retires From Tennis -- Update
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19307 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist